PHILADELPHIA and VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...
Independent DSMB reports no safety concerns to date and recommends continuing BriaCell’s pivotal Phase 3 ...
Now Enrolling Patients at Memorial Sloan Kettering Cancer Center (MSK) BriaCell Phase 3 trial featured ...
Cell-based immunotherapy program is designed to harness patients’ own immune systems Bria-MEL+ is a personalized, ...
FDA clearance of Investigational New Drug (IND) application enables BriaCell to initiate Phase 1/2a clinical ...
Sunnybrook’s Odette Cancer Centre, a world-class cancer center in Toronto, Ontario, Canada, joins BriaCell’s pivotal ...
Arrangement with FUJIFILM Biotechnologies California provides manufacturing capacity for the remainder of BriaCell’s pivotal Phase ...
Charles River Associates (CRA) to evaluate epidemiology, pricing, prescriber dynamics, and market access potential for ...
Agreement supports potential commercial readiness for Bria-IMT using Uneedle’s proprietary microneedle technology for intradermal administration ...
PHILADELPHIA & VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...
Accessibility Tools
